Chunxiao Wang

Dr. Chunxiao Wang


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2024 in Immunity, Inflammation and Disease
Verified
Journal Article
Open access
CWChunxiao Wang
Chunxiao Wang
WYWeihong Yan
Weihong Yan
MRMengmeng Ren
Mengmeng Ren
LZLin Zhong
Lin Zhong
Background: The incidence of coronary heart disease (CHD) in youth is rapidly increasing but difficultly recognized in the early stage.Methods and Results: In this retrospective study, 194 CHD patients under the age of 45 who previously experienced chest pain symptoms and 170 non‐CHD patients were included and demographic data were collected. Systemic inflammation index (SII) and systemic inflammation response index (SIRI) were increased in young CHD patients (p < 001). Spearman's correlation analysis showed that both SII and SIRI were negatively correlated with HDL and positively correlated with hypertension, Gensini score, and hsTnI. Logistic regression analysis indicated that SII and SIRI were independently associated with the presence of CHD in youth with chest pain symptoms. The area under the ROC curve (AUC) of the SII model for young CHD patients was 0.805 (0.728−0.869), and the sensitivity and specificity were 0.65 and 0.823, respectively. Meanwhile, the AUC for the SIRI model was 0.812 (0.739−0.872), and the sensitivity and specificity were 0.673 and 0.8022. The calibration curves of both SII and SIRI models are in good agreement with the actual curves. And the decision curves of both models indicated their clinical practicality.Conclusion: SII and SIRI are independent risk factors for CHD in young adults, which can quickly and effectively identify CHD patients among young adults who have previously experienced chest pain symptoms.

26 June 2021 in Liver International
Verified
Journal Article
Open access
PDF file
PGPeter R. Galle
Peter R. Galle
Masatoshi KudoMasatoshi Kudo
Masatoshi Kudo
JLJosep M. Llovet
Josep M. Llovet
RFRichard S. Finn
Richard S. Finn
MKMark Karwal
Mark Karwal
AZAndrew X. Zhu
Andrew X. Zhu
Background & Aims: Hepatocellular carcinoma (HCC) is a common complication of chronic liver disease with diverse underlying aetiologies. REACH/REACH‐2 were global phase III studies investigating ramucirumab in advanced HCC (aHCC) following sorafenib treatment. We performed an exploratory analysis of outcomes by liver disease aetiology and baseline serum viral load.Methods: Meta‐analysis was conducted in patients with aHCC and alpha‐fetoprotein (AFP) ≥400 ng/mL (N = 542) from REACH/REACH‐2 trials. Individual patient‐level data were pooled with results reported by aetiology subgroup (hepatitis B [HBV] or C [HCV] and Other). Pre‐treatment serum HBV DNA and HCV RNA were quantified using Roche COBAS AmpliPrep/COBAS TaqMan. Overall survival (OS) and progression‐free survival (PFS) were evaluated using the Kaplan‐Meier method and Cox proportional hazard model (stratified by study).Results: Baseline characteristics were generally balanced between arms in each subgroup (HBV: N = 225, HCV: N = 127, Other: N = 190). No significant difference in treatment effect by aetiology subgroup was detected (OS interaction P‐value = .23). Median OS (ramucirumab vs placebo) in months was 7.7 versus 4.5 (HR 0.74, 95% CI 0.55–0.99) for HBV, 8.2 versus 5.5 (HR 0.82, 95% CI 0.55–1.23) for HCV and 8.5 versus 5.4 (HR 0.56, 95% CI 0.40–0.79) for Other. Ramucirumab showed similar overall safety profiles across subgroups. Worst outcomes were noted in patients with a detectable HBV load. Use of HBV antiviral therapy, irrespective of viral load, was beneficial for survival, liver function and liver‐specific adverse events.Conclusions: Ramucirumab improved survival across aetiology subgroups with a tolerable safety profile, supporting its use in patients with aHCC and elevated AFP.

1 July 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YCYanan Chen
Yanan Chen
MRMengmeng Ren
Mengmeng Ren
CWChunxiao Wang
Chunxiao Wang
LZLin Zhong
Lin Zhong
Background Peripheral microangiopathy occurs in various diseases. However it is not known whether changes in the peripheral microcirculation are present in patients with coronary heart disease (CHD). Methods Two hundred and nineteen patients were enrolled. They were allocated to a control group and a CHD group according to coronary angiography findings and underwent nail fold videocapillaroscopy. Propensity score matching was used to match the two groups in a 1:1 ratio. Peripheral microangiopathy parameters were compared between the groups, and correlation were assessed between changes in the peripheral microcirculation and the severity of CHD. Results Overall, 95 patients were included in the control group and 124 in the CHD group. Patients in the CHD showed reduced capillary lengths, increased thrombosis, abnormal papilla and subpapillary venous plexuses, and a higher proportion of total score 2 compared with the controls. CHD severity was positively correlated with the numbers of crossed capillaries, thrombosis, abnormal papilla and total Score 2. After propensity score matching analysis, reduced apical width and capillary length were observed, while abnormal papillary and subpapillary venous plexuses were increased in patients with CHD, together with increases in the total scores. Conclusion The findings demonstrated that the effectiveness of peripheral microangiopathy in assessing CHD severity, providing a basis for CHD screening.


1 April 2026 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
MRMengmeng Ren
Mengmeng Ren
YWYiming Wang
Yiming Wang
LZLin Zhong
Lin Zhong
CWChunxiao Wang
Chunxiao Wang
Background: Ischemic stroke is a leading cause of death and disability worldwide. Identifying patients with carotid atherosclerosis who are at high risk is clinically important. Acute coronary syndrome (ACS) is a manifestation of systemic atherosclerosis, in which inflammation plays a key role in plaque progression and destabilization. However, the relationship between blood cell-derived systemic inflammation indices and carotid plaque burden in patients with ACS remains unclear. Methods: This retrospective study included 7,178 patients with ACS. Carotid ultrasound was used to classify patients into carotid plaque and non-plaque groups. Systemic inflammation indices—including neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), neutrophil-to-monocyte-plus-lymphocyte ratio (NMLR), systemic inflammatory response index (SIRI), systemic immune-inflammatory index (SII), aggregate index of systemic inflammation (AISI), and platelet-to-lymphocyte ratio (PLR)—were calculated from routine blood tests. Multivariable logistic regression, restricted cubic spline models, and subgroup analyses were used to evaluate their associations with carotid plaques. Results: Patients with carotid plaques had significantly higher NLR, MLR, NMLR, SIRI, SII, AISI, and PLR. After full adjustment, MLR, SIRI, and AISI showed significant non-linear associations with carotid plaques, with inflection points of 0.26, 0.9, and 205, respectively. Compared with the lowest quartile, the highest quartile was associated with increased odds of carotid plaques for MLR (OR 1.453), SIRI (OR 1.409), and AISI (OR 1.379). Subgroup analyses showed that these associations were mainly observed in women and in non-diabetic patients. In patients with hypertension, MLR, SIRI, and AISI remained positively associated with carotid plaques. Conclusion: MLR, SIRI, and AISI are independently associated with carotid plaques in patients with ACS, particularly among women and non-diabetic individuals, and may serve as potential markers for ischemic stroke risk stratification in this population.

21 September 2026 in Cell Biology International
Verified
Journal Article
Closed access
HSHan Sun
Han Sun
MSMengchen Sun
Mengchen Sun
YSYonghao Sheng
Yonghao Sheng
HWHua Wang
Hua Wang
XJXiaoyan Jiang
Xiaoyan Jiang
LZLin Zhong
Lin Zhong